Answers are grounded in this paper and cite their sources.
Presents a new screening method for acetylcholinesterase inhibitors in herbal extracts, suggesting potential Alzheimer's therapy benefits.
Current Alzheimer's drugs exhibit limited effectiveness, highlighting the necessity for multi‐target treatments. This study developed an innovative and efficient screening platform combining hydrogen peroxide test strip‐based colorimetric sensing with affinity chromatography for rapid identification of acetylcholinesterase (AChE) inhibitors from complex herbal medicines. Applying this strategy, from Lycium barbarum leaves, we identified three potent inhibitors: chlorogenic acid, N‐acetyl‐N'‐caffeoylputrescine (NANCP), and N‐caffeoylputrescine (NCP), with IC 50 ranging from 55.7 to 143.2 µ m . Molecular analyses confirmed their stable binding to AChE. In a D‐galactose and AlCl 3 ‐induced Alzheimer's disease (AD) mouse model, NCP treatment significantly rescued cognitive deficits in AD mice, with the spontaneous alternation rate in the Y‐maze test improved by up to 50%. It markedly reduced cerebral Aβ levels (by 54%) and pro‐inflammatory cytokines, including TNF‐α, IL‐1β, and IL‐6, alleviated oxidative stress, and attenuated hippocampal neuronal damage. Mechanistically, NCP modulated glycerophospholipid metabolism, reshaped gut microbiota, and targeted the proteasome‐autophagy pathway, revealing a multi‐faceted synergistic mechanism. The research offers a new screening tool for AChE inhibitors and highlights a promising natural multi‐target candidate, NCP, for AD therapy.
No takes yet. Share an insight, caveat, or question.
Sa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: